Alamar Biosciences' NULISA™ platform Nucleic acid Linked Immuno-Sandwich Assay addresses one of proteomics' oldest bottlenecks: reliably detecting low-abundance proteins buried within a plasma or serum sample's much larger dynamic range. By combining a dual capture-and-release mechanism with oligonucleotide-conjugated antibodies, the chemistry suppresses background signal at a level that is unmatched by conventional sandwich immunoassays and proximity ligation techniques. This pushes detection limits into the attomolar range, which is about 10,000 times more sensitive than traditional assay sensitivity. That gain in sensitivity is matched by an equally consequential gain in range: single-plex assays span up to seven logs of quantifiable concentration, while multiplexed panels extend to twelve logs, letting researchers measure scarce and abundant proteins side by side without serial dilution. Every step, from sample loading to sequencing-ready output, runs on Alamar's automated system, requiring under 30 minutes of hands-on time and accommodating up to 288 samples per batch. For laboratories working with limited liquid biopsy material, the combination of attomolar sensitivity, extended dynamic range, and streamlined automation positions NULISA as an increasingly referenced benchmark in ultra-low abundance biomarker research.
Sign in to leave a comment.